Illumina, which aims to usher in a new era of blood cancer, plans to buy GRAIL for $8 billion.

Today, Illumina and GRAIL jointly announced that they have reached a final agreement to acquire GRAIL for $8 billion in cash and stock.
acquisition will accelerate the development of transformative multi-cancer early screening tests, which are expected to lead to earlier cancer diagnosis and better clinical outcomes for patients.
GRAIL is an independent company founded by Illumina in 2016 to develop cutting-edge data science and machine learning based on Illumina's next-generation gene sequencing technology (NGS) and to create a map of cancer signals in the blood.
these advances make early detection of multiple cancers possible.
the company's multi-cancer early screening test Gallei was able to detect more than 50 cancer types, more than 45 of which were not recommended in the United States.
GRAIL plans to introduce Gallei testing in 2021.
references: Illumina to Acquire GRAIL to Launch New Era of Cancer Detection. Retrieved September 21, 2020, from . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .